This is a working overview of alpha-MSH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
NF-kappa+B at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Sankar Ghosh (2006). Handbook of Transcription Factor NF-κB. Boca Raton: CRC. ISBN 978-0-8493-2794-0. Thomas D Gilmore. "The Rel/NF-κB Signal Transduction Pathway". Boston University. Retrieved 2007-12-02.
Mammals are the best models for human disease, making genetic engineered ones vital to the discovery and development of cures and treatments for many serious diseases. Knocking out genes responsible for human genetic disorders allows researchers to study the mechanism of the disease and to test possible cures. Genetically modified mice have been the most common mammals used in biomedical research, as they are cheap and easy to manipulate. Pigs are also a good target as they have a similar body size and anatomical features, physiology, pathophysiological response and diet. Nonhuman primates are the most similar model organisms to humans, but there is less public acceptance towards using them as research animals. In 2009, scientists announced that they had successfully transferred a gene into a primate species (marmosets) for the first time. Their first research target for these marmosets was Parkinson's disease, but they were also considering amyotrophic lateral sclerosis and Huntington's disease. Human proteins expressed in mammals are more likely to be similar to their natural counterparts than those expressed in plants or microorganisms. Stable expression has been accomplished in sheep, pigs, rats and other animals. In 2009, the first human biological drug produced from such an animal, a goat, was approved. The drug, ATryn, is an anticoagulant which reduces the probability of blood clots during surgery or childbirth and is extracted from the goat's milk.
== Nanozymes == Nanozymes are nanomaterials exhibiting enzyme-like properties, first coined in 2004. They have applications in biosensing, bioimaging, tumor therapy, and anti-biofouling. Unlike natural enzymes, nanozymes offer stability, multifunctionality, and scalability.
=== EC 1.11.2 Peroxygenase === EC 1.11.2.1: unspecific peroxygenase EC 1.11.2.2: myeloperoxidase EC 1.11.2.3: plant seed peroxygenase EC 1.11.2.4: fatty-acid peroxygenase EC 1.11.2.5: 3-methyl-L-tyrosine peroxygenase EC 1.11.2.6: L-tyrosine peroxygenase
The Viceroyalty of New Granada was established in 1717, then temporarily removed, and then re-established in 1739. Its capital was Santa Fé de Bogotá. This Viceroyalty included some other provinces of northwestern South America that had previously been under the jurisdiction of the Viceroyalties of New Spain or Peru and correspond mainly to today's Venezuela, Ecuador, and Panama. Bogotá became one of the principal administrative centers of the Spanish possessions in the New World, along with Lima and Mexico City, though it remained less developed compared to those two cities in several economic and logistical ways. Great Britain declared war on Spain in 1739, and the city of Cartagena quickly became a top target for the British. A massive British expeditionary force was dispatched to capture the city, but, after achieving initial inroads, devastating outbreaks of disease crippled their numbers, and the British were forced to withdraw. The battle became one of Spain's most decisive victories in the conflict, and secured Spanish dominance in the Caribbean until the Seven Years' War. The 18th-century priest, botanist, and mathematician José Celestino Mutis was delegated by Viceroy Antonio Caballero y Góngora to conduct an inventory of the nature of New Granada. Started in 1783, this became known as the Royal Botanical Expedition to New Granada. It classified plants and wildlife, and founded the first astronomical observatory in the city of Santa Fe de Bogotá. In July 1801 the Prussian scientist Alexander von Humboldt reached Santa Fe de Bogotá where he met with Mutis.
Sources: en.wikipedia.org
29 June – A spokesman for Reform UK confirms the party has dropped three candidates for making offensive comments. They are Edward Oakenfull (Derbyshire Dales), Robert Lomas (Barnsley North), and Leslie Lilley (Southend East and Rochford), but the candidates will still appear on the ballot paper as Reform candidates because it is too late for them to be removed. East Lothian Council becomes the third local authority to establish an emergency facility for people who have not received their postal votes. The Northern Ireland Conservatives launch their election manifesto with the help of Chris Heaton-Harris, the Secretary of State for Northern Ireland. Policies include upholding the Good Friday Agreement and continuing to invest in Northern Ireland. The Conservatives are fielding five candidates in Northern Ireland. 30 June – The Sunday Times endorses the Labour Party for the first time since the 2001 general election. Liam Booth-Isherwood, the Reform UK candidate for Erewash, disowns the party, citing a "significant moral issue" following recent reports of "widespread racism and sexism", and gives his backing to the Conservatives.
The episode is now considered to be a serious breach of medical ethics and of the Hippocratic Oath. The government covered up most of these actions until 1993, when President Bill Clinton ordered a change of policy and federal agencies then made available relevant records. The resulting investigation was undertaken by the president's Advisory Committee on Human Radiation Experiments, and it uncovered much of the material about plutonium research on humans. The committee issued a controversial 1995 report which said that "wrongs were committed" but it did not condemn those who perpetrated them.
"Vitellogenin, juvenile hormone, insulin signaling, and queen honey bee longevity". Proceedings of the National Academy of Sciences. 104 (17): 7128–33. Bibcode:2007PNAS..104.7128C. doi:10.1073/pnas.0701909104. PMC 1852330. PMID 17438290.
=== Andy: Get The Poison Out === First aired: 4 November 2010 Meet Andy, the self-appointed king of Fresno. He is an obnoxious bully who makes life miserable for his victims, Steven and Taylor. He also makes the biggest mistake of calling out Mayhem, so Mayhem brings out "the greatest fighter he has ever known" to take care of Andy. That fighter turns out to be Mayhem himself. After easily being tapped out 5 times in the first round and knocked out in the second round, Steven and Taylor won $10,000. After the fight, Mayhem tells a humbled Andy that he had to deal with bullies most of his life and implores him to change his ways because he eventually will come across someone that is bigger, badder and meaner than Andy himself.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.